Capricor/$CAPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Ticker
$CAPR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
160
ISIN
US14070B3096
Website
Capricor Metrics
BasicAdvanced
$327M
-
-$1.42
0.86
-
Price and volume
Market cap
$327M
Beta
0.86
52-week high
$21.01
52-week low
$3.52
Average daily volume
3.4M
Financial strength
Current ratio
6.548
Quick ratio
6.484
Long term debt to equity
0.319
Total debt to equity
0.998
Profitability
EBITDA (TTM)
-55.832
Gross margin (TTM)
-232.78%
Net profit margin (TTM)
-317.13%
Operating margin (TTM)
-329.90%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-35.24%
Return on equity (TTM)
-75.39%
Valuation
Price to revenue (TTM)
15.995
Price to book
2.56
Price to tangible book (TTM)
2.56
Price to free cash flow (TTM)
-5.887
Free cash flow yield (TTM)
-16.99%
Free cash flow per share (TTM)
-121.62%
Growth
Revenue change (TTM)
-35.92%
Earnings per share change (TTM)
65.27%
3-year revenue growth (CAGR)
339.82%
10-year revenue growth (CAGR)
12.12%
3-year earnings per share growth (CAGR)
13.88%
10-year earnings per share growth (CAGR)
-14.49%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Bulls say / Bears say
Capricor Therapeutics' lead product, Deramiocel (CAP-1002), is advancing through a Phase 3 clinical trial for Duchenne muscular dystrophy (DMD), with potential FDA approval expected in Q4 2025, which could significantly boost revenue upon successful commercialization. (Investing.com)
The company has a strong cash position of $151.5 million as of Q4 2024, providing a financial runway into 2027, allowing sustained investment in research and development without immediate financing concerns. (Investing.com)
Analysts have a consensus 'Strong Buy' rating for CAPR stock, with an average 12-month price target of $33.75, indicating a potential upside of over 229% from the current price. (StockAnalysis.com)
In 2024, Capricor's revenue declined by 11.55% to $22.27 million, and net losses increased by 81.6% to $40.47 million, raising concerns about the company's financial sustainability. (StockAnalysis.com)
The company's return on equity stands at -75.39%, reflecting significant operational inefficiencies and potential challenges in achieving profitability. (DirectorsTalkInterviews)
Capricor's stock has experienced high volatility, with a 52-week range between $3.52 and $23.40, which may deter risk-averse investors. (CNBC)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Capricor News
AllArticlesVideos
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
GlobeNewsWire·2 hours ago
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
GlobeNewsWire·2 hours ago
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)
GlobeNewsWire·5 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $327M as of July 18, 2025.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of July 18, 2025.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.